Endoscopic Technologies for Peripheral Pulmonary Lesions: From Diagnosis to Therapy

Fantin, Alberto; Manera, Massimiliano; Patruno, Vincenzo; Sartori, Giulia; Castaldo, Nadia; Crisafulli, Ernesto

doi:10.3390/life13020254

Cited by 4 publications

(2 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDT diagnostics has exciting potential in LC management, and compared with traditional bronchoscopic methods that only have a 30% sensitive for early detection ( 40 ), fluorescence bronchoscopy has significantly higher specificity and sensitivity. It can thus can enhance the detection of preinvasive lesions and early invasive carcinoma involving the central airway and directly observe the course of the disease, effectively improving the prognosis of patients with LC ( 41 , 42 ).…”

Section: Discussionmentioning

confidence: 99%

Bibliometric and visual analysis of photodynamic therapy for lung cancer from 2010 to 2022

Gu,

Wu,

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background A growing body of research shows that photodynamic therapy (PDT) has become an important mode of treatment in the field of lung cancer (LC) in recent years. Although numerous papers related to PDT in LC have been published, no bibliometric studies have been conducted to summarize the research prospects and highlight the research trends and hotspots in this field. This bibliometric analysis was conducted to investigate and provide a systematic understanding of the development of PDT research for LC over the past 13 years with the aim of providing a reference for new directions and strategies in the field of PDT for LC. Methods In May 2023, relevant publications from the Web of Science Core Collection were downloaded, and CiteSpace and VOSviewer were used to conduct the scientometrics analysis in this study. Results A total of 2,932 articles and reviews that met the inclusion criteria were retrieved, with China dominated the volume of publications from 2010 to 2022 and the most prolific institution was Shanghai Jiao Tong University. Conclusions PDT can be utilized for the diagnosis and treat LC. Bronchoscopic fluorescence diagnosis using photosensitizers helps to detect tumor changes in the large bronchial mucosa. In the future, we should actively explore the use of new photosensitizers, including the development of nanomaterials, in addition, PDT combined with other treatments can significantly prolong survival. This combination therapy may also be the direction of future research.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometric and visual analysis of photodynamic therapy for lung cancer from 2010 to 2022

Gu,

Wu,

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…With the advent of lung cancer screening programs, lung cancer may be detected at an earlier stage when peripheral pulmonary lesions are found in the absence of a central tumor mass. For these peripheral nodules, bronchoscopy with transbronchial biopsy is a routine diagnostic tool ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Comparison of transbronchial biopsy techniques using needle and forceps biopsies in lung cancer for molecular diagnostics: a prospective, randomized crossover trial

Sticht,

Malfertheiner,

Wiest

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background In lung cancer, molecular testing and next-generation sequencing (NGS) are needed to identify therapeutic targets and are increasingly being used in earlier stages of the disease. Despite its longstanding use, it remains unclear whether transbronchial needle aspiration (TBNA) of peripheral lung lesions provides as adequate material for genetic testing as transbronchial forceps biopsies (TBFBs). In this study, we aim to analyze the use of TBNA using median viable cell area (MVCA) as a surrogate parameter to analyze sample quality. Methods This prospective single-center study analyzed biopsy specimens or aspirates of patients who underwent bronchoscopy with transbronchial biopsy. Patients underwent bronchoscopy with TBFB and TBNA for suspected lung cancer in peripheral lung lesions. Patients were randomized 1:1 to receive either TBFB or TBNA as the first biopsy technique and then switched to the other. After routine workup, sample slides were digitally scanned, and MVCA was calculated by a pathologist blinded to the biopsy technique used. The primary endpoint was MVCA of TBNA versus TBFB. Secondary endpoints were complications categorized as bleeding, pneumothorax, and other. Results Between August 2021 and April 2022, 15 patients were included in the per-protocol analysis. Six patients were included in cohort 1 and nine patients in cohort 2. A malignant diagnosis was confirmed in 11/15 (73.3%) cases, of which nine were primary lung malignancies. Overall, MVCA in samples obtained by TBFB was significantly larger than TBNA samples {TBFB-MVCA 9.80 mm 2 [interquartile range (IQR), 2.70–10.39 mm 2 ] vs . TBNA-MVCA 2.70 mm 2 (IQR, 0.14–8.21 mm 2 ), P=0.008}. Despite this difference, molecular testing was feasible in both TBNA and TBFB samples. No major complications were observed. Conclusions Despite a significantly smaller MVCA provided by TBNA, samples were still considered feasible for NGS, indicating that TBNA represents an alternative method to obtain sufficient tumor tissue in peripheral nodules as part of the diagnosis of suspected lung cancer.

show abstract

Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?

Pagliari,

Colonese,

Canova

et al. 2024

Cancers

View full text Add to dashboard Cite

According to a modern view, cancer no longer follows a purely mechanistic model. Rather, a tumor is conceived as a more complex structure, composed of cancer cells, the activities of which may interact and reshape the so-called tumor microenvironment (TME), leading to preservation of specific tumoral niches and promoting the survival of tumoral stem cells. Background/Objective: Therapeutic strategies must deal with this unique cancer architecture in the near future by widening their range of activities outside the cancer cells and rewiring a TME to ensure it is hostile to cancer growth. Therefore, an intratumoral therapeutic strategy may open the door to a new type of anticancer activity, one that directly injures the tumoral structure while also eliciting an influence on the TME through local and systemic immunomodulation. This review would like to assess the current situation of intratumoral strategies and their clinical implications. Methods We analyzed data from phase I, II, and III trials, comprehensive reviews and relevant clinical and preclinical research, from robust databases, like PUBMED, EMBASE, Cochrane Library, and clinicaltrials.gov. Results: Intratumoral strategies can be quite variable. It is possible the injection and inhalation of traditional antiblastic agents or immunomodulant agents, or intrapleural administration. Ablation strategy is available, both thermal and photodynamic method. Moreover, TTfields and NPs are analyzed and also brachytherapy is mentioned. Intratumoral therapy can find space in “adjuvant”/perioperative or metastatic settings. Finally, intratumoral strategies allow to synergize their activities with systemic therapies, guaranteeing better local and systemic disease control. Conclusions: Intratumoral strategies are overall promising. Antiblastic/immunomodulant injection and NPs use are especially interesting and intriguing. But, there is generally a lack of phase II and III trials, in particular NPs use need additional experimentation and clinical studies.

show abstract

Endoscopic Technologies for Peripheral Pulmonary Lesions: From Diagnosis to Therapy

Cited by 4 publications

References 183 publications

Bibliometric and visual analysis of photodynamic therapy for lung cancer from 2010 to 2022

Bibliometric and visual analysis of photodynamic therapy for lung cancer from 2010 to 2022

Comparison of transbronchial biopsy techniques using needle and forceps biopsies in lung cancer for molecular diagnostics: a prospective, randomized crossover trial

Intratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?

Contact Info

Product

Resources

About